Since its establishment, basic and clinical research has been an integral part of the Division of Immunotherapy and Autoimmune Diseases (DIAD) at Northwestern University. Our physicians are world leaders in the areas of stem cell research and clinical trials.
We are committed to finding answers to today's most disabling and puzzling medical problems. Working collaboratively with the scientists of Northwestern University Feinberg School of Medicine, our physicians are translating exciting research advances discovered in the laboratory into more effective treatment approaches and prevention strategies for our patients.
To learn more about our stem cell research and immunotherapy,
please contact us: 312-503-4190.
About the Multiple Sclerosis (MS) Trial:
Multiple sclerosis (MS) is an autoimmune disease in which the nerves of the central nervous system (brain and spinal cord) degenerate. Multiple Sclerosis is at onset an immune-mediated disease. In most cases, it starts as a relapsing—remitting disease with distinct attacks and no progression between flares. Over time, most cases transition into a progressive disease which means a slow neurologic deterioration without acute flares . Relapsing remitting disease is often responsive to immune–based therapies while, in general, it is ineffective in the more severe progressive stages of the disease.
Northwestern University, the University of Calgary and the University of Sao Paulo, Brazil have partnered to offer patients with relapsing-remitting inflammatory MS, a randomized study utilizing autologous stem cell transplantation versus the FDA approved standard of care (i.e. interferon, Copaxone®, mitoxantrone or Tysabri®) View the study design >
